Cadrenal Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CVKD Nasdaq 2834 www.cadrenal.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients - Jun 12th, 2025 6:00 am
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 - Jun 4th, 2025 6:00 am
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin… - May 19th, 2025 8:41 am
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness - May 15th, 2025 5:30 am
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update - May 8th, 2025 6:00 am
Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans? - Apr 6th, 2025 7:16 am
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences - Apr 3rd, 2025 6:00 am
CVKD: Preparing for Phase 3 Trial of Tecarfarin… - Mar 31st, 2025 8:24 am
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin - Mar 13th, 2025 2:05 pm
CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial… - Mar 7th, 2025 6:15 am
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin - Mar 5th, 2025 5:28 am
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - Mar 4th, 2025 6:00 am
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin - Feb 6th, 2025 7:00 am
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference - Feb 5th, 2025 7:00 am
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Jan 9th, 2025 6:44 am
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications - Dec 31st, 2024 6:00 am
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings - Dec 18th, 2024 7:00 am
CVKD: Recent Financings Raise $9.8 Million… - Nov 20th, 2024 6:03 am
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - Nov 19th, 2024 7:00 am
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS - Nov 12th, 2024 7:00 am